Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto
|
|
- Candice Robbins
- 6 years ago
- Views:
Transcription
1 Int J Clin Oncol (2013) 18:75 80 DOI /s ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in patients with bladder cancer Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Received: 5 August 2011 / Accepted: 24 October 2011 / Published online: 8 November 2011 Ó Japan Society of Clinical Oncology 2011 Abstract Background This study retrospectively evaluated the clinical relevance of transurethral prostate biopsy (TUPB) before radical cystectomy by comparing the pathology of prostatic urethra biopsy specimens with that of cystectomy specimens. Methods Of 294 patients who underwent cystectomy and urinary diversion, 101 men with preoperative TUPB were included in this study. For these patients, if the result of TUPB was positive for urothelial carcinoma, we performed urethrectomy as a rule. If it was negative, we presented the option of urethral preservation and decided the final type of urinary reconstruction. The sensitivity, specificity, and positive and negative predictive values (PPV and NPV) of TUPB were assessed, and we investigated the number of final urethral recurrences. We also tried to identify which clinical and pathological findings by TUPB most accurately predicted the remaining in the prostate of cystectomy specimens. Results Of the 25 patients with positive TUPB, 18 had in the prostatic urethra or stroma of cystectomy specimens. There were 3 patients with negative TUPB but with involvement of the prostate in cystectomy specimens. Thus, TUPB achieved 86% sensitivity, 91% specificity, 72% PPV, and 96% NPV. Two patients (1.9%) had urethral recurrence in this period. Among the findings for TUPB, non-papillary tumors most accurately predicted the in the prostate of cystectomy specimens. K. Ichihara (&) H. Kitamura N. Masumori F. Fukuta T. Tsukamoto Department of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, , Japan kichi@sapmed.ac.jp Conclusions TUPB achieved a high NPV and the urethral recurrence rate was acceptable. If TUPB was negative, patients could have chance urethral preservation. Thus, our clinical decision for urethrectomy based on the result of TUPB is still useful. Keywords Bladder neoplasms Prostatic urethra Biopsy Cystectomy Patient selection Introduction Radical cystectomy with pelvic lymph node dissection and urinary diversion is the standard treatment for muscleinvasive and high-risk non-muscle-invasive bladder carcinoma. Previous reports have suggested that % of male patients will develop urethral recurrence after radical cystectomy [1 5]. Risk factors for recurrence include tumors located at the bladder neck, multifocal tumors, concomitant diffuse carcinoma in situ (CIS), a positive urethral margin, tumor in the prostatic urethra or prostatic stromal invasion, and non-orthotopic urinary diversion [6, 7]. In particular, diffuse bladder CIS extending to the prostatic urethra is a sign of high risk for synchronous involvement of cancer in the anterior urethra [8]. During the last 15 years, we have done simultaneous transurethral prostate biopsy (TUPB) together with standard transurethral resection of bladder tumors (TURBT) before cystectomy to determine the indication for urethrectomy in male patients. However, the clinical significance of this biopsy before radical cystectomy is controversial. Several studies have indicated that intraoperative frozen section pathology of the urethral margin during cystectomy is more reliable for determining the indication for urethrectomy [9, 10].
2 76 Int J Clin Oncol (2013) 18:75 80 Here we retrospectively compared the pathological results of radical cystectomy specimens with those of TUPB, and investigated the final urethral recurrence. Moreover, we reassessed the clinical relevance of TUPB. Our study confirmed that the procedure is still clinically useful for the selection of appropriate patients for urethrectomy. Patients and methods We had 294 male and female patients who received radical cystectomy with urinary diversion for bladder carcinoma from January 1990 to December Of the 234 male patients, 101 were included in this study after exclusion of 10 with cystectomy for the purpose of maintaining quality of life, 62 with neoadjuvant chemotherapy, 17 with a previous history of or simultaneous association with urothelial carcinoma (UC) in the upper urinary tract, 11 with UC in the prostate that directly invaded from the bladder, 31 without TUPB, and 2 with incomplete medical records. Among the 62 male patients with neoadjuvant chemotherapy, 39 with TUPB were separately evaluated. Institutional review board approval was obtained for the study. All patients had preoperative standard evaluations for extension and the clinical state was determined according to their results. The stage of the bladder cancer was determined using the 2002 revision of the TNM [11]. Radical cystectomy was indicated for patients with highgrade non-muscle-invasive UC or those with muscleinvasive UC who had no apparent pelvic lymph node involvement or distant metastasis. At our hospital, we performed TUPB together with TURBT to assess whether the urethra could be preserved. In the case of positive shown by TUPB, we basically performed urethrectomy together with cystectomy to avoid urethral recurrence. On the other hand, if the result of TUPB was negative, the urethra was preserved. The technique for the prostate biopsy is to resect the prostatic urethra transurethrally at the 5 and 7 o clock positions from the bladder neck to the verumontanum. We confirmed sufficient resection of the prostatic stromal tissue as well as the mucosa of the urethra. We determined the sensitivity and specificity, positive predictive value (PPV), and negative predictive value (NPV) of TUPB based on the final pathology of cystectomy specimens. UC in the prostatic urethra was defined as in the mucosa or stroma of the prostate that was separately present from the bladder lesion. This is because urethrectomy is usually done together with cystectomy, based on the fact that extending directly to the urethra from the bladder is a high-risk condition for urethral recurrence when the urethra is preserved. In this study, 11 patients were excluded from the final examination for this reason. As indicated above, 39 patients with neoadjuvant chemotherapy were evaluated separately because chemotherapy may have influenced the final pathology results. MVAC therapy, consisting of methotrexate, vinblastine, doxorubicin and cisplatin, was given with a median of 2 courses. We also evaluated the clinicopathological variables of TUPB, which might be useful in predicting remaining UC involving the prostate or prostatic urethra in cystectomy specimens. These variables were the configuration of the dominant tumor (papillary or non-papillary), tumor grade (grade 3 or \3 grade), tumor located at the bladder neck (yes or no) and prostatic urethra (yes or no), tumor extension to the prostatic stroma in TUPB (yes or no), concomitant CIS (yes or no), and previous recurrence (yes or no). After surgery, patients were followed up with routine blood tests, computed tomography from the lung to pelvis and a bone scan (if indicated) to assess recurrence of the. Surveillance of urethral recurrence was performed via history and physical examination. If patients had bleeding from the preserved urethra, washing cytology with endoscopic examination was indicated. If patients with a neobladder had hematuria, endoscopic examination of the lower urinary tract was indicated. Image diagnosis of the upper urinary tract was also indicated if necessary. Statistical analysis was done using the chi-squared test and Fisher s exact test. Differences were considered significant at P \ Results Patients characteristics The characteristics of patients are summarized in Table 1. The median follow-up period was 44 months, ranging from 1.4 to 175 months. A total of 25 of the 101 patients (24.7%) were identified as having UC in the prostatic urethra before cystectomy, whereas the final pathological examination of cystectomy specimens revealed that the remained in the urethra in 21 patients (20.7%). Results of TUPB and the status of the urethral margin in cystectomy specimens Among the 25 patients positive for UC in the prostatic urethra or stroma by TUPB, 18 (17.8%) had that remained in the same area of cystectomy specimens (Table 2). There were 3 patients (2.9%) with negative TUPB but with involvement of the prostate in cystectomy
3 Int J Clin Oncol (2013) 18: Table 1 Patients characteristics Age (years), median, (range) 68 (44 83) Clinical stage, n (%) BT1 10 (10) T2 33 (33) T3 33 (33) T4 25 (25) Concomitant carcinoma in situ 7 (7) Tumor grade, n (%) Grade 1 0 Grade 2 24 (24) Grade 3 75 (75) Unclear 2 (2) Pathological stage, n (%) BT1 34 (34) T2 12 (12) T3 20 (20) T4 17 (17) N(?) 18 (18) Type of urinary diversion, n (%) Ileal conduit 68 (67) Ileal neobladder 29 (29) Others 4 (4) Table 2 Disease status in the prostate specimens obtained by TUPB and radical cystectomy Prostate specimens from TUPB with positive with negative Total no. of patients Prostate specimens from radical cystectomy with positive TUPB transurethral prostatic biopsy with negative Total no. of patients specimens. Thus, the sensitivity of TUPB for the was 86%, specificity 91%, PPV 72%, and NPV 96%. No patients were diagnosed as having a positive urethral margin in cystectomy specimens. Among the 3 patients with negative UC in the prostate by TUPB but positive in cystectomy specimens, one died of cancer-related peritonitis 1 month after cystectomy. The other two patients had no recurrence of the during the follow-up period (62 and 74 months, respectively). Table 3 Predictive factors for UC remaining in the prostatic urethra and stroma of cystectomy specimens in 25 patients with positive TUPB Variables identified by TUPB UC-positive in Cx specimen (18 patients), n (%) UC-negative in Cx specimen (7 patients), n (%) Variables for prediction of UC that remained in the prostatic urethra and stroma of cystectomy specimens in patients with positive TUPB Table 3 shows the results of statistical analysis. In the clinicopathological findings of TUPB before cystectomy, the configuration of the main tumor most accurately predicted whether the remained in the prostatic urethra or stroma of cystectomy specimens (P = 0.03). Concomitant CIS and a history of recurrence were found only in patients with positive UC in cystectomy specimens. Impact of neoadjuvant chemotherapy on the final pathology P value a Tumor grade Grade 3 14 (78) 5 (71) [0.99 \Grade 3 4 (22) 2 (29) Configuration of tumor Non-pap. 12 (67) 1 (14) 0.03 Pap. 6 (33) 6 (86) Tumor at bladder neck Yes 14 (78) 6 (86) [0.99 No 4 (22) 1 (14) Tumor extension to prostatic stroma Yes 7 (39) 2 (29) [0.99 No 11 (61) 5 (71) Visible tumor at prostatic urethra Yes 11 (61) 3 (43) 0.66 No 6 (39) 4 (57) Concomitant CIS Yes 5 (28) No 13 (72) 7 (100) History of recurrence Yes 7 (39) No 11 (61) 7 (100) UC urothelial carcinoma. TUPB transurethral prostatic biopsy, nonpap. non-papillary, pap. papillary, Cx radical cystectomy, CIS carcinoma in situ a Fisher s exact test A total 39 patients with TUPB received neoadjuvant chemotherapy before cystectomy. Of the 8 patients who were positive for UC in the prostatic urethra or stroma by TUPB, only 1 had that remained in the same area of cystectomy specimens. There were 4 patients with negative
4 78 Int J Clin Oncol (2013) 18:75 80 TUPB but with involvement of the prostate in cystectomy specimens. The sensitivity and PPV decreased to 20 and 12.5%, respectively, but the specificity and NPV remained at 79 and 87%, respectively. Final urethral recurrence Of the 101 patients, 2 (1.9%) had urethral recurrence after cystectomy. One patient was positive for the by TUPB, and received urethrectomy with cystectomy, and pathological examination showed that no remained in the specimen. However, UC recurred in the meatus of the glans at 7 months after surgery. The other patient was negative for the by TUPB and no was detected in cystectomy specimens of the prostate. However, UC recurred in the preserved urethra at 24 months after cystectomy and ileal conduit. These 2 patients received resection of the urethral remnant or urethrectomy after diagnosis, but died of the at 41 months and 48 months after urethrectomy, respectively. Discussion UC in the prostatic urethra and stroma is one of risk factors for postoperative urethral recurrence and it is important to evaluate this area before cystectomy. UC in the prostatic urethra or stroma is clearly associated with the clinical courses of patients [12 16]. However, because not all patients develop urethral recurrence, we need to identify appropriate candidates to avoid unnecessary urethrectomy. We performed TUPB for evaluation of the prostatic urethra and stroma when the standard TURBT was done. If the patient was positive for UC according to the results of TUPB, we performed urethrectomy together with cystectomy. In this study, the prostate biopsy achieved 72% PPV and 96% NPV. These results suggested that TUPB was a relevant examination for identifying that remained in the prostate of cystectomy specimens. Thus, when TUPB is negative, preservation of the urethra is highly possible without compromising the patient. This situation allows us to safely recommend orthotopic urinary diversion for patients, because the final pathology of the prostatic urethra and stroma of the cystectomy specimen will be negative for the. It is said that orthotopic urinary diversion may have favorable aspects from the point of view of body image and almost normal voiding condition [17]. In addition, patients and urologists as well are more comfortable when they know whether the urethra can be preserved and can determine the type of urinary diversion before cystectomy. On the other hand, previous reports suggested a low efficacy of TUPB, and supported the relevance of examining intraoperative frozen sections of the urethral margin [9, 10]. Lebret et al. [10] reported that they performed TUPB and also obtained frozen sections from 118 patients, and 9 patients had positive TUPB but negative frozen sections. Based on these results, these 9 patients did not receive urethrectomy. However, none of them had urethral recurrence for 10 years after surgery, and none of the patients with negative frozen sections were positive for TUPB. Kassouf et al. [9] reported that, in 22 of 177 (among 252) neobladder patients who received TUPB, tumors were detected at the prostatic urethra, but only one patient had a tumor at the urethral margin of a radical cystectomy specimen (non-prostatic region). Donat et al. [18] reported that TUPB could not evaluate tumor invasion of the prostate precisely because it had a low PPV (about % in their report) and did not reflect urethral recurrence. However, our results support the clinical relevance of TUPB for decision-making on urethral preservation. As described above, we found two patients with urethral recurrence. It is said that the TUPB result does not reflect urethral recurrence precisely. The rate of recurrence in the current study was not significantly different from those of previous studies. Thus, the clinical decision for urethral preservation based on the TUPB result does not generate a clinical disadvantage for patients who receive radical cystectomy. Moreover, 72% PPV does not necessarily imply low clinical relevance for TUPB. That is, if TUPB produces a positive result, there will be a nearly 30% chance for patients to have no in cystectomy specimens. The incidence of the in the prostate according to the cystectomy specimen may depend on the examination method. When a whole mount pathology section is used for this purpose, the incidence increases to 40% [19, 20], although routine pathology yields 20% [21 23]. Therefore, we emphasize the significance of NPV rather than PPV. If the result of TUPB was negative, UC in the prostatic urethra of the cystectomy specimen was negative with high probability. In addition, if the urethra was preserved based on the negative TUPB result, recurrence in the preserved urethra was also highly unlikely. Whatever the procedure is, all we need to do is to identify patients who are very unlikely to have urethral recurrence, which provides patients with more opportunities for urethral preservation and thus for orthotopic urinary reconstruction. At present, our clinical practice may recommend preservation of the urethra and orthotopic urinary reconstruction when TUPB is negative. When TUPB is positive, urethrectomy is basically proposed for patients. However, in this situation, intraoperative frozen sections of the urethral margin may be a practical way to make a final decision if patients strongly desire urethral preservation and orthotopic urinary reconstruction. In this study, we also investigated PPV and NPV in patients who received neoadjuvant chemotherapy. PPV
5 Int J Clin Oncol (2013) 18: was low (12.5%), but NPV was comparatively high (87%). The chemotherapy may have induced downstaging of the in these patients. In fact, of 8 patients with positive TUPB, 7 were negative for UC of the prostatic urethra in the final pathology and 5 had pt0 or pt1 in the final specimen. However, in patients with neoadjuvant chemotherapy, there were 4 patients who were negative in TUPB but positive in cystectomy specimens. Thus, we need further study to determine the impact of chemotherapy on in the prostatic urethra. Finally, we tried to identify specific clinical features of patients who were revealed to have UC in the prostatic urethra of cystectomy specimens among those who had a positive TUPB. Mazzucchelli et al. [24] reported that tumor diameter ([5 cm), a tumor located at the bladder neck and a history of recurrence were risk factors for positive UC in the prostatic urethra of cystectomy specimens. In our study, a non-papillary tumor was such a factor. If we establish risk factors more concretely, these together with the result of TUPB will select more appropriate patients who really need urethrectomy. The limitations of our study include the small number of patients and its retrospective nature. In addition, patients without TUPB were excluded from the study. These may have contributed to a potential selection bias of the study. Thus, a prospective study with a larger number of patients will be needed to reach a final conclusion. Conclusions We evaluated the clinical relevance of TUPB before cystectomy in this study. TUPB achieved a high NPV and the number of final urethral recurrences was acceptable. Thus, a clinical decision on urethrectomy based on the result of TUPB is still useful. Our clinical practice may recommend preservation of the urethra when TUPB is negative. On the other hand, the configuration of the main bladder tumor was related to the agreement between the pathology of TUPB and that of cystectomy specimens. Therefore, this variable and/or intraoperative frozen section of the urethral margin may be a practical way to make a final decision if patients with positive TUPB strongly desire urethral preservation and orthotopic urinary reconstruction. Conflict of interest this manuscript. References No author has any conflict of interest regarding 1. Hassan JM, Cookson MS, Smith JA Jr et al (2004) Urethral recurrence in patients following orthotopic urinary diversion. J Urol 172: Freeman JA, Tarter TA, Esrig D et al (1996) Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 156: Bell CR, Gujral S, Collins CM et al (1999) Review. The fate of the urethra after definitive treatment of invasive transitional cell carcinoma of the urinary bladder. BJU Int 83: Levinson AK, Johnson DE, Wishnow KI (1990) Indications for urethrectomy in an era of continent urinary diversion. J Urol 144: Stenzl A, Bartsch G, Rogatsch H (2002) The remnant urothelium after reconstructive bladder surgery. Eur Urol 41: Freeman JA, Esrig D, Stein JP et al (1994) Management of the patient with bladder cancer. Urethral recurrence. Urol Clin N Am 21: Kakizoe T, Tobisu K (1998) Transitional cell carcinoma of the urethra in men and women associated with bladder cancer. Jpn J Clin Oncol 28: Tobisu K, Kanai Y, Sakamoto M et al (1997) Involvement of the anterior urethra in male patients with transitional cell carcinoma of the bladder undergoing radical cystectomy with simultaneous urethrectomy. Jpn J Clin Oncol 27: Kassouf W, Spiess PE, Brown GA et al (2008) Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol 180: Lebret T, Hervé JM, Barré P et al (1998) Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur Urol 33: Sobin DH, Wittekind CH (2002) Classification of malignant tumors. TNM classification of malignant tumors, 6th edn. Wiley- Liss, Inc., New York, pp Esrig D, Freeman JA, Elmajian DA et al (1996) Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 156: Pagano F, Bassi P, Ferrante GL et al (1996) Is stage pt4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J Urol 155: Herr HW, Donat SM (1999) Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J Urol 161: Cheville JC, Dundore PA, Bostwick DG et al (1998) Transitional cell carcinoma of the prostate: clinicopathologic study of 50 cases. Cancer 82: Wishnow KI, Ro JY (1988) Importance of early treatment of transitional cell carcinoma of prostatic ducts. Urology 32: Meyer JP, Fawcett D, Gillatt D et al (2005) Orthotopic neobladder reconstruction what are the options? BJU Int 96: Donat SM, Wei DC, McGuire MS et al (2001) The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol 165: Reese JH, Freiha FS, Gelb AB et al (1992) Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol 147: Wood DP Jr, Montie JE, Pontes JE et al (1989) Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol 141: Stein JP, Clark P, Miranda G et al (2005) Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 173: Iselin CE, Robertson CN, Webster GD et al (1997) Does prostate transitional cell carcinoma preclude orthotopic bladder recons-
6 80 Int J Clin Oncol (2013) 18:75 80 truction after radical cystoprostatectomy for bladder cancer? J Urol 158: Njinou Ngninkeu B, Lorge F, Moulin P et al (2003) Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol 169: Mazzucchelli R, Barbisan F, Santinelli A et al (2009) Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. Urology 74:
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationRadical cystectomy with or without urethrectomy?
Critical Reviews in Oncology/Hematology 47 (2003) 141/145 www.elsevier.com/locate/critrevonc Radical cystectomy with or without urethrectomy? Hein Van Poppel *, Tomas Sorgeloose Division of Urology, University
More informationUrethral recurrence after cystectomy: current preventative measures, diagnosis and management
Urethral recurrence after cystectomy: current preventative measures, diagnosis and management Yvonne Chan*, Patrick Fisher*, Derya Tilki* and Christopher P.Evans* *Department of Urology, Medical Center,
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationOptimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder
Jpn J Clin Oncol 2002;32(1)14 18 Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder Isao Hara, Hideaki Miyake, Shoji Hara, Akinobu Gotoh, Hiroshi
More informationAnterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience
DOI 10.1186/s40064-015-1200-7 RESEARCH Open Access Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience Nozomi Hayakawa 1,2*, Nobuyuki Kikuno 1,2, Hiroki
More informationPartial Cystectomy for Invasive Bladder Cancer
European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationIncidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens
Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens Harman Maxim Bruins,* Hooman Djaladat,* Hamed Ahmadi, Andy
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationHaijun Zhou, Jae Y Ro, Luan D Truong, Alberto G Ayala, Steven S Shen
Am J Clin Exp Urol 2014;2(2):156-160 www.ajceu.us /ISSN:2330-1910/AJCEU0000048 Original Article Intraoperative frozen section evaluation of ureteral and urethral margins: studies of 203 consecutive radical
More informationTCC recurrence within the upper tract urothelium following
Upper Tract Urothelial Recurrence Following Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: An Analysis of 1,069 Patients With 10-Year Followup Kristin M. Sanderson,* Jie Cai, Gustavo
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationOrgan-sparing treatment of invasive transitional cell bladder carcinoma
Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More information5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.
Bladder Case Scenario 1 History 5/23/16: A 52-year-old male, smoker was admitted to our hospital with a 3-month history of right pelvic pain, multiple episodes of gross hematuria, dysuria, and extreme
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationYASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI
Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationBladder replacement in men and women: when and when not? Outline. Continent Diversion History
1 Bladder replacement in men and women: when and when not? Eila C. Skinner, MD Professor of Clinical Urology Keck USC School of Medicine Outline 1) Selection criteria for orthotopic diversion: Tumor-related
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationInfluence of stage discrepancy on outcome in. in patients treated with radical cystectomy.
Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationUrethral Carcinoma Recurrence in Ileal Orthotopic Neobladder: Urethrectomy and Conversion in a Continent Pouch with Abdominal Stoma
Case Report Urol Int 1999;62:213 216 Received: June 19, 1998 Accepted after revision: March 8, 1999 Urethral Carcinoma Recurrence in Ileal Orthotopic Neobladder: Urethrectomy and Conversion in a Continent
More informationCase 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:
Case 1 89 year old male with initial occurrence of gross hematuria Office flexible cystoscopy shows two papillary tumors with some surface necrosis Complete TURBT into muscle Florescence cysto shows two
More informationInformation for Patients. Primary urethral cancer. English
Information for Patients Primary urethral cancer English Table of contents What is primary urethral cancer?... 3 Risk factors... 3 Symptoms... 4 Diagnosis... 4 Clinical examination... 4 Urinary cytology...
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationThe pathology of bladder cancer
1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new
More informationA215- Urinary bladder cancer tissues
A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: No. of cases: 45 Tissue type: Urinary bladder cancer tissues No. of spots: 2 spots from each cancer case (90
More informationInformation for Patients. Bladder Cancer. English
Information for Patients Bladder Cancer English Table of contents What is the function of the bladder?... 3 What is bladder cancer?... 3 What causes bladder cancer?... 3 Stages of the disease... 3 Risk
More informationRadical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients
EUROPEAN UROLOGY 61 (2012) 1039 1047 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant
More informationA Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density
Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma
More informationSecond transurethral resection against Ta high grade tumor:residual location and predictive factor. A single center, retrospective study
Japanese Journal of Endourology(2018)31:108-112 Original Article CJapanese Society of Endourology 2018 Tetsuya Shindo Naotaka Nishiyama Naoya Masumori Second transurethral resection against Ta high grade
More informationBJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.
2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical
More informationBone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?
Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko
More informationMultiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules URINARY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationDr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate
Dr. Tareq Salah Ahmed,MD,ESMO Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate 1 st Assiut Urology department conference,marsa Alam 3 rd February 2015 Bladder cancer
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationNeo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder
Annals of Oncology : -5. 999. 999 Klimer Academic Publishers. Printed in the Netherlands. Original article Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma
More informationCase Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationInvasive Bladder Transitional Cell Carcinoma OBJECTIVES
Invasive Bladder Transitional Cell Carcinoma UBC Urology Grand Rounds 7 September 2005 John Morrell R5 OBJECTIVES Review role of lymphadenectomy Review role of chemotherapy Review results of bimodal bladder
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Outcome of Open Radical Cystectomy and Ileal Conduit: A Single Center Experience Mahesh Kalloli
More informationIs Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?
Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan
More informationMEDitorial March Bladder Cancer
MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting
More informationPure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder
Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationPanel: A Case-based Approach to the Management of Bladder Cancer
Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.
More informationNeoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,
More informationBladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)
Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationROBOTIC VS OPEN RADICAL CYSTECTOMY
ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/96833
More informationREVIEW. Patterns of recurrence of bladder carcinoma following radical cystectomy
Cancer Imaging (2003) 3, 96 100 DOI: 10.1102/1470-7330.2003.0009 CI REVIEW Patterns of recurrence of bladder carcinoma following radical cystectomy D M Koh and J E Husband Academic Department of Radiology,
More informationEAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
EAU MUSLE-INVASIVE AND METASTATI LADDER ANER (Limited text update March 2016) J.A. Witjes (hair), E. ompérat, N.. owan, M. De Santis, G. Gakis, N. James, T. Lebret, A.G. van der Heijden, M.J. Ribal Guidelines
More informationmodels; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns.
; 21 Urological Oncology MUSCULARIS PROPRIA AND UPSTAGING OF ct1 BLADDER CANCER BADALATO ET AL. BJUI Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationMultiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy
Brazilian Journal of Medical and Biological Research (2007) 40: 979-984 Predictive factors after radical cystectomy ISSN 0100-879X 979 Multiple factor analysis of metachronous upper urinary tract transitional
More informationINCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER
& INCIDENTAL PROSTATE CANCER IN PATIENTS UNDERGOING RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER Mustafa Hiroš *, Hajrudin Spahović, Mirsad Selimović, Sabina Sadović Urology Clinic, University of Sarajevo
More informationDisease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy
European Urology European Urology 41 2002) 440±448 Disease Speci c Survival as Endpoint of Outcome for Bladder Cancer Patients Following Radical Cystectomy JuÈrgen E. Gschwend a,b,*, Philipp Dahm c, WilliamR.
More informationPart II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by
Women & Bladder Cancer A Woman-to-Woman Talk with Dr. Armine Smith Wednesday, March 8, 2017 Part II: Treatment Presented by Dr. Smith is an Assistant Professor of Urology at Johns Hopkins University and
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationImpact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
More informationChemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008
Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation
More informationBladder-Sparing Treatment of Invasive Bladder Cancer
Several alternatives to radical cystectomy for muscle-invasive bladder cancer have been studied. None, however, are reliably superior to operative treatment. Sidi Bou Said,Tunisia, 1999. Courtesy of J.
More informationSuperficial Urothelial Cancer in the Prostatic Urethra
Review Article Superficial Bladder Cancer TheScientificWorldJOURNAL (2006) 6, 2603 2610 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2006.402 Superficial Urothelial Cancer in the Prostatic Urethra Ziya
More informationCould salvage surgery after chemotherapy have clinical impact on cancer survival of patients with
Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? Kensuke Bekku, Takashi Saika, Yasuyuki Kobayashi, Ryo Kioshimoto, Taiki
More informationAUA Guidelines for Invasive Bladder Cancer: What s New?
AUA Guidelines for Invasive Bladder Cancer: What s New? Michael S. Cookson, MD, MMHC Professor and Chairman Department of Urology, University of Oklahoma History 1999: AUA guidelines Panel Non-muscle invasive
More informationUpdate on bladder cancer diagnosis and management
7 Update on bladder cancer diagnosis and management RICHARD T. BRYAN Although the basis of the diagnosis and management of urothelial bladder cancer has remained unchanged for two decades or more, there
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationOpen Radical Cystectomy Tips and Tricks in Males and Females
Open Radical Cystectomy Tips and Tricks in Males and Females Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationBladder Sparing Treatment of Muscle Invasive Bladder Cancer
Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy
More informationTOPICS FOR DISCUSSION
INTERNATIONAL SOCIETY OF UROLOGIC PATHOLOGY PATHOLOGIC STAGING OF SELECT UROLOGIC MALIGNANCIES Mahul B. Amin, MD Professor and Chairman Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationThe Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma
Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationSurgical Management of Bladder Carcinoma
The critical principles and controversies in both the endoscopic and open surgical approaches to superficial and invasive bladder cancer are reviewed. Anita Philyaw. Bookmark (detail), 2000. Acrylic on
More informationRadiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer
Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Z. AKÇETIN 1, J. TODOROV 1, E. TÜZEL 1, D.G. ENGEHAUSEN 1, F.S. KRAUSE 1, R. SAUER 2, K.M. SCHROTT
More informationHighlighting Clinical Trials Muscle Invasive Bladder Cancer
Highlighting Clinical Trials Muscle Invasive Bladder Cancer Part I: The Basics of MIBC Clinical Trials June 19, 2018 Presented by: Dr. Peter Black is a urologic oncologist at Vancouver General Hospital,
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More informationTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Jeffrey M. Holzbeierlein, MD, FACS John W Weigel Professor & Chair Director of Urologic Oncology University of Kansas
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationPlasmacytoid Variant Urothelial Carcinoma: Diagnostic and Grossing Challenges. Kailyn Gibson MS, PA-ASCP, Congli Wang, MD
1 Plasmacytoid Variant Urothelial Carcinoma: Diagnostic and Grossing Challenges Kailyn Gibson MS, PA-ASCP, Congli Wang, MD Johns Hopkins Hospital Department of Surgical Pathology 2 Plasmacytoid Variant
More information